Full-Time

Head of Bioinformatics and Data Science

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Biotechnology
Healthcare

Compensation Overview

$267k - $280kAnnually

+ Bonus + Incentives + Restricted Stock Units

Senior, Expert

San Bruno, CA, USA

Hybrid position.

Category
Bioinformatics
Biology & Biotech
Data & Analytics
Required Skills
Data Science
Data Analysis
Requirements
  • Ph.D. in Biostatistics, Bioinformatics, Computational Biology, Computer Science, or a related field.
  • 10+ years of experience in leadership roles within the healthcare technology or diagnostics industry.
  • Strong understanding of genomics, molecular diagnostics, and personalized medicine.
  • Proven track record of successfully developing clinical genomic testing with a preference for those with experience in Oncology testing.
  • Experience with applied data science, real world evidence, and big data analytics in healthcare applications.
  • Ability to translate complex technical concepts into business value propositions.
  • Experience in managing cross-functional teams and driving collaborative projects.
  • Excellent leadership, communication, and interpersonal skills.
  • Ability to work collaboratively in a fast-paced, interdisciplinary environment.
  • Experience with regulatory submissions and compliance.
Responsibilities
  • Lead the strategic direction of the Data Analysis Team (DAT department), aligning with Veracyte's overall business objectives and vision.
  • Oversee the development and implementation of current and future genomic clinical tests.
  • Collaborate with cross-functional teams including R&D, Product Development, IT, Clinical Affairs, and others to discover, develop, and evolve clinical testing and support Veracyte's diagnostic platforms.
  • Drive innovation in data analytics and bioinformatics to extract meaningful insights from complex genomic and clinical data.
  • Lead a team of bioinformaticians, biostatisticians, and data scientists, providing strategic direction and mentorship.
  • Support partnerships with external technology providers, academic institutions, and industry leaders to stay at the forefront of technological advancements.
  • Ensure compliance with regulatory requirements and industry standards for digital health technologies.
  • Develop and manage the departmental budget and resource allocation.
  • Represent Veracyte at conferences, industry events, and stakeholder meetings to promote the company's technological capabilities.

Veracyte specializes in cancer diagnostics by developing advanced genomic tests that assist in the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, providing crucial insights into the presence and progression of cancer. This allows healthcare providers, including hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve patient outcomes and enhance the efficiency of cancer treatment through accurate and early diagnosis.

Company Stage

IPO

Total Funding

$69.4M

Headquarters

San Francisco, California

Founded

N/A

Growth & Insights
Headcount

6 month growth

5%

1 year growth

7%

2 year growth

10%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recognition as a Bay Area Top Workplace for 11 consecutive years highlights a positive work environment and strong company culture.
  • Significant investments from firms like Aigen Investment Management and Quest Partners indicate strong financial backing and growth potential.
  • The upcoming launch of ClearLab and an MRD assay in 2026 showcases Veracyte's commitment to expanding its product portfolio and market reach.

What critics are saying

  • The competitive landscape in genomic diagnostics is intense, requiring Veracyte to continuously innovate to maintain its market position.
  • Dependence on successful clinical validation and regulatory approval for new tests can pose risks to product launch timelines.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection, setting it apart from traditional diagnostic methods.
  • Their Decipher Prostate and Bladder Genomic Classifiers offer superior prognostic information compared to standard approaches, enhancing treatment personalization.
  • Continuous investment in R&D and clinical validation ensures that Veracyte's tests remain at the forefront of cancer diagnostics.

Help us improve and share your feedback! Did you find this helpful?